Free Trial
NASDAQ:TVTX

Travere Therapeutics (TVTX) Stock Price, News & Analysis

Travere Therapeutics logo
$17.50 -0.20 (-1.13%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$17.52 +0.02 (+0.11%)
As of 08/29/2025 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Travere Therapeutics Stock (NASDAQ:TVTX)

Key Stats

Today's Range
$17.43
$17.94
50-Day Range
$14.49
$18.82
52-Week Range
$8.98
$25.29
Volume
1.96 million shs
Average Volume
1.75 million shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.43
Consensus Rating
Moderate Buy

Company Overview

Travere Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

TVTX MarketRank™: 

Travere Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 583rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Travere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Travere Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Travere Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Travere Therapeutics are expected to grow in the coming year, from ($1.40) to ($0.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Travere Therapeutics is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Travere Therapeutics is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Travere Therapeutics has a P/B Ratio of 23.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Travere Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    12.44% of the float of Travere Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Travere Therapeutics has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in Travere Therapeutics has recently decreased by 17.42%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Travere Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Travere Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.44% of the float of Travere Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Travere Therapeutics has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in Travere Therapeutics has recently decreased by 17.42%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Travere Therapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Travere Therapeutics this week, compared to 7 articles on an average week.
  • Search Interest

    2 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,940.00 in company stock.

  • Percentage Held by Insiders

    Only 4.19% of the stock of Travere Therapeutics is held by insiders.

  • Read more about Travere Therapeutics' insider trading history.
Receive TVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TVTX Stock News Headlines

Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it.tc pixel
Travere Therapeutics (NASDAQ:TVTX) Cut to "Hold" at Wall Street Zen
See More Headlines

TVTX Stock Analysis - Frequently Asked Questions

Travere Therapeutics' stock was trading at $17.42 at the start of the year. Since then, TVTX stock has increased by 0.5% and is now trading at $17.50.

Travere Therapeutics, Inc. (NASDAQ:TVTX) issued its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.14. The firm's revenue for the quarter was up 111.5% on a year-over-year basis.
Read the conference call transcript
.

Top institutional shareholders of Travere Therapeutics include Armistice Capital LLC (9.96%), Adage Capital Partners GP L.L.C. (3.12%), Emerald Advisers LLC (2.36%) and Geode Capital Management LLC (2.26%). Insiders that own company stock include Eric M Dube, Peter Heerma, William E Rote, Christopher R Cline, Jula Inrig, Jeffrey A Meckler, Elizabeth E Reed, Sandra Calvin, Gary A Lyons and Roy D Baynes.
View institutional ownership trends
.

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Home Depot (HD), Walmart (WMT), Netflix (NFLX), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Company Calendar

Last Earnings
8/06/2025
Today
9/01/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TVTX
CIK
1438533
Employees
460
Year Founded
N/A

Price Target and Rating

High Price Target
$47.00
Low Price Target
$20.00
Potential Upside/Downside
+91.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$321.55 million
Net Margins
-50.64%
Pretax Margin
-50.65%
Return on Equity
-717.68%
Return on Assets
-30.69%

Debt

Debt-to-Equity Ratio
9.50
Current Ratio
2.00
Quick Ratio
1.98

Sales & Book Value

Annual Sales
$333.87 million
Price / Sales
4.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.76 per share
Price / Book
23.03

Miscellaneous

Outstanding Shares
89,139,000
Free Float
85,520,000
Market Cap
$1.56 billion
Optionable
Optionable
Beta
0.78

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:TVTX) was last updated on 9/1/2025 by MarketBeat.com Staff
From Our Partners